



The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid



Original article

Nicotinamide activates latent HIV-1 *ex vivo* in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294



Sadia Samer^a, Muhammad Shoaib Arif^b, Leila Bertoni Giron^c, Jean Paulo Lopes Zukurov^d, James Hunter^e, Bruna Teresa Santillo^f, Gislene Namiyama^g, Juliana Galinkas^e, Shirley Vasconcelos Komninakis^e, Telma Miyuki Oshiro^f, Maria Cecilia Sucupira^e, Luiz Mario Janini^d, Ricardo Sobhie Diaz^{id e,*}

^a Yerkes National Primate Research Center, Emory University, Atlanta, Georgia

^b Department of Cell and Developmental Biology, Feinberg School of Medicine, Northwestern University, Chicago, USA

^c Wistar Institute, Philadelphia, USA

^d Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo, São Paulo, SP, Brazil

^e Department of Medicine, Federal University of Sao Paulo, São Paulo, SP, Brazil

^f Department of Dermatology, University of Sao Paulo, São Paulo, SP, Brazil

^g Department of Electron Microscopy, Institute of Adolfo Lutz, São Paulo, SP, Brazil

ARTICLE INFO

Article history:

Received 4 October 2019

Accepted 31 January 2020

Available online 24 February 2020

Keywords:

Nicotinamide

Latency reversal agents

Histone deacetylases inhibitor

Methyltransferase inhibitors

Chaetocin

BIX01294

ABSTRACT

Background: Latent HIV-1 is a major hurdle in obtaining HIV-1 sustained virological remission (SVR). Here we explored histone deacetylation inhibition property of nicotinamide (NAM; n = 17) for the first time in comparison to a combination of methyltransferase inhibitors (MTIs; Chaetocin and BIX01294; n = 25) to reactivate latent HIV *ex vivo* in CD8-depleted PBMCs from antiretroviral treated aviremic individuals.

Results: NAM reactivated HIV-1 from 13/17 (76.4%) samples compared to 20/25 (80.0%) using MTIs with mean viral load (VLs) of 4.32 and 3.22 log₁₀ RNA copies/mL, respectively (p = 0.004). Mean purging time after NAM and MTIs stimulation was 5.1 and 6.75 days, respectively (p = 0.73). Viral purging in autologous cultures exhibited blunted HIV recovery with fluctuating VLs followed by a complete viral extinction when expanded in allogenic system. Electron microscopy from five supernatants revealed anomalous viral particles, with lack of complete viral genomes when characterized by ultradeep sequencing through metagenomics approach (n = 4).

* Corresponding author.

E-mail address: rsdiaz@catg.com.br (R.S. Diaz).

<https://doi.org/10.1016/j.bjid.2020.01.005>

1413-8670/© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Conclusion: NAM alone was more potent HIV-1 activator than combination of MTIs, with potential of clinical use.

© 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Even with effective antiretroviral therapy (ART), a cure for HIV remains elusive due to persistent viral replication in lymphoid tissues and latent resting CD4+ T lymphocytes.¹

Being latent, HIV remains hidden from the immune cells and ART, and long lived resting memory CD4+ T lymphocytes are believed to represent the predominant reservoir of proviruses.² Latency reversal agents (LRAs) have helped to interrupt the dormant state of HIV so that HIV expression can be induced, followed by clearance of that cell by viral cytopathic effects, immune clearance or antiretrovirals.³ Many distinct LRAs (Vorinostat, Romidopsin,⁴ Chaetocin,⁵ Panobinostat,⁶ BIX01294,⁷ Thalidomide⁸) have demonstrated the ability to inhibit chromatin condensation, restore suppressor gene expression and exert antitumor effects in many *in vitro* and *in vivo* studies. Hypoacetylation is one of the best characterized modifications where histone deacetylases (HDACs) cleave the acetyl group from amino groups of lysine residues in histone tails of nucleosomes. This results in condensed chromatin with less transcription factors accessibility, therefore silencing the gene. Cofactor dependence and sequence homology divide HDACs into two families and four different classes (I–IV). The classic HDAC family (classes I, II, and IV) needs a zinc ion at the catalytic site to cause deacetylase activity while the Silent Information Regulator 2 (Sir2)-related protein (sirtuin) family (class III HDACs) requires nicotinamide adenine dinucleotide (NAD) as a cofactor for its catalytic activity and shows no sequence homology to classical zinc-dependent HDACs.⁹

There are many pathways that can convert NAM into nicotinamide mononucleotide (NMN) through the enzyme nicotinamide phosphoribosyltransferase (NMPRTase).¹⁰ NMN can then be directly converted into NAD by nicotinic acid/nicotinamide mononucleotide adenyltransferase (NMNAT) which is active for NMN substrates.¹¹ NAM released in the reaction inhibits SIRT1 through the so-called base exchange pathway, wherein rebinding of the reaction product to the enzyme accelerates the reverse reaction with an intermediate in the catalytic cycle instead of deacetylation reaction.¹² Sirtuins are thus regulated by their cofactor NAD as well as their reaction product NAM that acts as their inhibitor.

The regulation of HIV-1 transcription is an interplay of both viral and host cellular components such as nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB).¹³ NFκB, being a critical regulator of HIV transcription, recruits the positive transcription elongation factor b (P-TEFb) to the viral 5'LTR, with the help of which only deacetylated form TAT protein binds to transactivation response element (TAR) that forms a stable RNA stem loop at the 5' end of all viral

transcripts.¹⁴ As the p65 subunit of NFκB and TAT are substrates of SIRT1,¹⁵ TAT binds to SIRT1 and is deacetylated. This binding might inhibit SIRT1's further deacetylation activity and thus helps in setting p65 subunit of NFκB free to carry out its function, leading to T cell hyperactivation.¹⁶

Since NAM has been shown to affect SIRT1 activity,^{11,17} we used NAM to revert HIV latency in comparison to a combination of two MTIs, Chaetocin and BIX01294 that respectively inhibit SUV39 and G9a, with ability to revert HIV latency.^{5,7} We demonstrated that NAM alone is more efficient in breaking latency than a combination of MTIs, in comparing the time and viral loads of the samples *ex vivo*.

Methods

A total of 40 HIV-1 positive volunteers were recruited from the Aids Clinic of the Federal University of São Paulo, Brazil according to the following inclusion criteria: 18 years old or more, voluntarily signed Informed Consent Form (ICF), on ART with undetectable viral loads for at least three years, current CD4+T lymphocytes count greater than 350 cells/μL. This study and the ICF have been approved by the Ethical Review Board in Brazil (# number 226.613, CAAE 10757312.0.000.5505). Recruited individuals were also part of a clinical trial aiming the reduction of latent HIV proviral reservoir (www.clinicaltrials.gov; ID: NCT02961829). Characteristics of these patients are reported in Table 1.

PBMCs from HIV-infected individuals and healthy donors were isolated by Ficoll-Hypaque gradient (GE Healthcare, Uppsala, Sweden) from 100 mL of whole blood. To avoid cytotoxic effects in cultures, CD8 T cells were depleted by EasySep Human CD8 Positive Selection kit (STEMCELL TECHNOLOGIES) and were cryopreserved in fetal bovine serum (FBS; Gibco) with 10% DMSO.

CD8-depleted PBMCs using the EasySep Human CD8 Positive Selection kit II (STEMCELL TM TECHNOLOGIES, Vancouver, Canada) were treated at a density of 10⁷ cells with either 10 mM NAM¹⁸ or a combination of 90 nM Chaetocin¹⁹ and 10 μM BIX-01294⁷ for 48 h and cultivated in RPMI medium (supplemented with 10% FBS and IL-2 20 IU/mL). Cell viability was assessed by cell counting after staining with trypan blue, and the cells were also closely monitored under the microscope. If the number of cells was on increase, it was assumed that the cells were proliferating and there was no drug associated cytotoxic effects. No drug associated cytotoxicity was observed after the treatment. Cells were always clumped together (healthy cells) rather than isolated cell suspension, and the overall viability was always above 70%.

After 48 h, cells were washed to remove excess PHA and LRAs and were cultivated in RPMI. Cultures were fed weekly with 10⁷ CD8-depleted autologous PBMCs, previously acti-

Table 1 – Demographic, virologic and immunological characteristics of samples treated with MTIs and NAM *ex vivo*.

IDs	Sex	Age	HIV diagnosis	Proviral Load (copies/10 ⁶ cells)	VL before treatment (log ₁₀)	Nadir CD4 (cells/μL)	Current CD4 (cells/μL)	Treatment initiation	ARV	Trop/Sub	LRA <i>in vitro</i> treatment
S1	M	52	2002	277.70	4.73	178	450	2002	TDF/3TC/ATV-r	R5/B	C + B
S2 ^a	M	46	2010	50.31	3.52	505	505	2010	TDF/3TC/EFV	R5/B	C + B
S3	M	51	1997	44.00	4.18	220	513	2000	LPV-r/EFV	R5/B	C + B
S4 ^a	M	54	2005	49.00	5.44	460	1230	2005	TDF/3TC/EFV	R5/B	C + B
S5	M	43	1995	268.00	5.13	213	592	1998	AZT/3TC/EFV	R5/B	C + B
S6 ^a	M	30	2005	91.00	4.08	354	919	2010	TDF/3TC/ATV-r	X4/B	C + B; NAM
S7	M	34	2010	42.00	4.79	836	1155	2011	TDF/3TC/EFV	X4/B	C + B
S8	M	46	2006	106.27	5.57	259	581	2007	TDF/3TC/EFV	X4/B	C + B
S9	M	41	2007	28.52	4.76	685	1010	2011	TDF/3TC/EFV	R5/C	C + B
S10	M	54	2005	NA	4.52	450	999	2005	TDF/3TC/EFV	R5/A/AG	C + B
S11	M	52	2000	515.90	5.00	50	552	2001	ABV/3TC/ATV-r	X4/B	C + B
S12	M	48	2005	63.00	4.75	265	889	2009	ABV/3TC/FPV-r	R5/B	C + B
S13	M	42	2000	Neg	4.48	330	650	2008	TDF/3TC/ATV-r	R5/B	C + B
S14	M	42	1998	98.00	4.90	200	590	2009	TDF/3TC/LPV-r	X4/B	C + B
S15	M	46	2000	241.00	4.74	100	652	2006	TDF/3TC/FPV-r	R5/NA	C + B
S27	M	30	2010	NA	4.11	589	1397	2012	AZT/3TC/EFV	R5/F	C + B
S30	M	32	NA	NA	NA	NA	1288	2013	TDF/3TC/NVP	R5/C	C + B
S31	M	25	NA	NA	NA	NA	846	2012	ABC/3TC/ATV-r	R5/B	C + B
S32	M	35	2002	NA	4.35	466	1128	2011	AZT/3TC/NVP	R5/F	C + B
S34	M	52	2013	NA	NA	658	658	2013	TDF/3TC/EFV	R5/B	C + B
S35	M	58	NA	NA	NA	NA	972	2007	AZT/3TC/EFV	R5/B	C + B
S40	M	24	2013	NA	5.72	490	842	2013	TDF/3TC/ATV-r	R5/B	C + B
S41	M	42	NA	NA	NA	NA	1816	2007	TDF/3TC/FPV-r	R5/B	C + B
S43	M	29	NA	NA	NA	NA	817	2009	TDF/3TC/ATV-r	R5/B	C + B
NA1	M	47	2007	NA	5.16	23	678	2005	AZT/3TC/LPV-r	NA/NA	NAM
NA2	F	39	2002	NA	4.87	95	500	2005	TDF/3TC/LPV-r	R5/B	NAM
NA3	M	44	2004	NA	5.34	9	908	2005	AZT/3TC/ATV-r	R5/B	NAM
NA4	M	30	2008	NA	7.00	386	942	2005	TDF/3TC/EFV	NA/NA	NAM
NA5	M	66	2010	NA	5.24	206	317	2005	AZT/3TC/EFV	R5/B	NAM
NA6 ^a	M	42	2012	NA	5.97	46	675	2005	TDF/3TC/LPV-r	R5/B	NAM
NA7	M	46	2001	NA	NA	44	712	2005	AZT/3TC/ATV-r	NA/NA	NAM
NA8	M	52	1988	NA	5.68	161	874	1997	TDF/3TC/EFV	R5/B	NAM
NA9	M	39	2013	NA	4.58	470	851	2013	TDF/3TC/EFV	NA/NA	NAM; C + B
NA10	M	38	2007	NA	NA	412	1250	2012	AZT/3TC/EFV	R5/B	NAM
NA11	M	31	2012	NA	4.31	375	686	2012	EFV/TDF/3TC	R5/B	NAM
NA12	M	47	2005	NA	NA	471	479	2005	TDF/3TC/EFV	R5/B	NAM
NA13	M	28	2013	NA	4.07	404	594	2013	TDF/3TC/EFV	R5/B	NAM
NA14	M	53	2010	NA	5.56	552	1056	2011	TFV/3TC/EFV	R5/B	NAM
NA15	M	37	NA	NA	4.40	418	1192	2012	AZT/3TC/EFV	R5/B	NAM
NA16	M	24	2013	NA	5	210	824	2013	AZT/3TC/EFV	X4/B	NAM

C + B: Chaetocin + BIX01294; NAM: Nicotinamide; ID: individuals identification; NA: Not available; VL: viral load (copies/mL); ARV: antiretrovirals; TDF: tenofovir; AZT: zidovudine; ABV: abacavir; 3TC: lamivudine; EFV: efavirenz; NVP: nevirapine; ATV-r: ritonavir boosted atazanavir; LPV-r: ritonavir boosted lopinavir; FPV-r: ritonavir boosted Fosamprenavir; Trop: Co-receptor tropism; X4: non-R5 tropic HIV; R5: R5 tropic virus; Sub: Viral subtype.

^a These samples stayed negative in initial attempts and were treated multiple times either with MTIs or NAM alone or combination of both.

vated with PHA and treated with LRAs for 48 h. We assumed that extracellular virions would accumulate over the course of several days; therefore, the supernatants were withdrawn every 3–4 days, while replenishing the cultures with fresh medium, for monitoring viral purging by the quantification of viral RNA with qPCR (Abbott Real Time HIV-1 assay, Abbott, Chicago, IL, USA). Viability was always checked before starting the culture using Neubauer chamber with trypan blue stain and was 90–95%.

We separated 2×10^7 cells from samples S1-S5 (samples C.S1 - C.S4; Fig. 1A) and NA1-NA4 (C.NA1-C.NA4; Fig. 1B) and used as controls without LRAs. Due to limited numbers of

autologous cells, the controls were kept over a period of 10 days only, seeded twice with 10^7 PHA activated autologous cells. The reagents Chaetocin (C9492), BIX-01294 (B9311) and Nicotinamide (N3376) were purchased from Sigma Aldrich (St. Louis, USA).

Depending upon the availability of PBMCs, buffy coat or culture supernatants, total DNA and RNA were extracted using Qiagen DNA Blood Mini Kit (Qiagen, Hilden, Germany) and Qiagen Viral RNA Mini Kit (Qiagen, Hilden, Germany), respectively, following the manufacturer's instructions.

HIV proviral loads were measured by qPCR using the HIV-1 LTR sequence as the target and the human CCR5 gene as




Fig. 1 – Ex vivo treatment with MTIs and NAM and their comparison.

(A) Graph showing the Log₁₀ viral load (copies/mL) of the culture supernatant treated with MTIs, (B) Graph showing the Log₁₀ viral load (copies/mL) of the culture supernatant treated with NAM, (C) Comparison of NAM + MTIs to break latency with respect to time. (D) Comparison of NAM + MTIs with respect to viral load.

the normalizer. We extrapolated copy numbers from standard curves generated with plasmids harboring the CCR5 and the HIV sequence, as previously described.²⁰ The reaction mixture consisted of 20 μ L of Gene expression master mix (Life Technologies, Carlsbad, CA, and USA Applied Biosystems, Coutabouef, France) 2X, 0.75 μ M of each oligonucleotide, 0.3 μ M of each probe, 5 μ L of sample, and DNase RNase-free water with total volume of 20 μ L. Sequences of primers and probes and cycling conditions have been previously described.²⁰

Viral tropism was inferred either by proviral DNA or viral RNA extracted from culture supernatants as previously described.^{21,22} The generated DNA sequences were aligned and edited manually for the codon alignment using BioEdit Version 7.2.5. The Geno2pheno_[correceptor] algorithm (available at <http://www.coreceptor.geno2pheno.org>) with an FPR cutoff of 10% was used to infer co-receptor tropism.

Metagenomics methodology was implied to *de novo* characterize supernatant samples containing purged HIV-1 particles following *in vitro* treatment with LRAs. RNA from supernatant was extracted using QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instruction. Extracted RNA was followed by reverse transcription into cDNA using random primers and SuperScript III-Reverse

transcriptase (Invitrogen) and the pre-amplification step was performed to enrich the viral nucleic acids as previously described.²³ Libraries were prepared using Nextera XT DNA Sample Preparation Kit (Illumina, San Diego, CA, USA) and sequenced using Illumina MiSeq platform.

Sequencing reads with Phred quality score over 30% (i.e., a base call accuracy of 99.9%) were aligned using Tanden (Tool for Analysis of Diversity in Viral Populations) software that performs the mapping and indexing of each short read, being utilized in data banks with 1258 reference sequences, including representatives of group M of HIV with all subtypes and recombinants, HIV group O and some SIVcpz sequences. The aligned sequences were validated according to their E-values and the distance from the reference sequence.

p24 was quantified in culture supernatants by ELISA Zep-toMetrix kit (ZeptoMetrix Corporation, Buffalo, New York), according to manufacturer's instructions.

Morphology of HIV particles was analyzed by TEM in fresh culture supernatants. TEM was performed as previously described with modifications.²⁴ Briefly, formvar-carbon-coated 300 mesh copper grids were treated with 30 μ L of Alcian Blue solution in 1% acetic acid for 10 min. Then, the grids were rinsed using three drops of sterile distilled water. After removal, with filter paper, grids were placed onto 30 μ L

of culture supernatants for 10 min. RPMI was used as negative control. Staining was carried out by successively transferring the grids to three drops of 2% potassium phosphotungstate (ph 7.2), dried with filter paper, and keeping at least 24 h at room temperature before the analysis mission electron microscopy. Grids were observed under a JEOL TEM (model JEM1011; JEOL/Massachusetts/USA) operating at 80 kV. Images were recorded with a charged-couple device camera (model 785 ES1000W, Gatan, USA) and the Gatan program version 1.6.

All statistical analyses were conducted using the R Statistical Language and Computing System, version 3.3.2. Kruskal-Wallis rank sum non-parametric chi-squared test were performed using Desc function of the DescTools package. In all cases a p-value of ≤ 0.05 was considered statistically significant. All the Graphs were developed using GraphPad Prism (v6.0).

Results

NAM is more potent activator of HIV in ex vivo primary cultures than a combination of MTIs (Chaetocin and BIX01294)

To assess LRAs for their ability to bring HIV out of latency, we used previously described MTIs and a novel SIRT1 inhibitor, NAM, in *ex vivo* cultures of CD8-depleted PBMCs from HIV-1 infected, ART treated patients who had undetectable viral loads over a period of at least three years. HIV latency reversal was detected using a commercial viral load assay in the supernatants from cultures by qPCR using the Automated 2000 System (Abbott, IL, USA), which has a dynamic range of detection from 40 to 1×10^7 copies of the HIV-1 RNA/mL. In terms of virus reactivation, both LRAs schemes displayed varying levels of potency in inducing HIV expression, although a wide standard deviation was observed in the magnitude of viral purging for both LRAs schemes (Fig. 1D).

Among samples treated with MTIs, 20/25 samples (80%) showed viral purging with a mean duration of 6.75 days (range: 3–29; Fig. 1A) and among the samples treated with NAM (n = 17), thirteen (76.4%) showed positivity of the cultures as inferred by the viral load result, with a mean time of 5.1 days (range; 3–17; Fig. 1B). No HIV-1 recovery was detected in control samples, which were not subjected to the action of the LRAs used in the experiment.

We then compared the purging potential of NAM and MTIs by considering time duration that LRAs took to break latency and their resulting viral loads. The proportion of positive samples treated with NAM was superior to the proportion of MTIs in the earliest category of purging – less than three days (52.8% for NAM against 40% for the MTI). Thereafter, the two types of treatment were roughly equivalent in the proportion of samples that demonstrated purging. Therefore, considering time across all samples tested for each LRA to break latency, no significant statistical difference was observed between the two groups (Chi-square test; n = 42, p = 0.7323 (2-tailed); Fig. 1C).

We compared the viral loads of supernatants at first positive collection. In this case, NAM showed higher mean \log_{10} viral load (4.32 copies/ml) than MTIs (3.22 copies/ml) and this difference was found to be significant (Chi-square test,

p = 0.004551; Fig. 1D). These findings suggest that activation of HIV transcription with NAM is more potent than MTIs.

LRAs manifest variable ex vivo HIV-1 activation in longitudinal samples from the same individual

In order to determine whether HIV-1 reactivation by these LRAs was consistent in samples collected longitudinally from the same patient, four samples were selected that showed no HIV-activation in initial attempts. RNA levels were measured from these samples treated with LRAs from the same individuals collected several months apart. Two of the tested samples (S2 and S4) showed HIV-1 activation at third attempt after the treatment with MTIs. While the other two samples (S6 and NA9) remained negative despite several attempts of the treatment with MTIs or NAM alone or even in combination. These findings showed that there are inter-patient variations in *ex vivo* HIV activation by MTIs or NAM.

Viral purging is independent of proviral load and viral tropism

We were able to quantify proviral DNA in 14 out of 25 individuals treated with MTIs *in vitro* with a median of 140.2 copies/ 10^6 PBMCs (range: 28.5–515.9). In 3/5 of negative cultures one sample was also negative for proviral load (Table 1). From both LRAs treatment, approximately 80% of the individuals showed R5 tropism (Table 1). However, no correlation was found between proviral load/viral tropism and purging (Supplementary Fig. S1).

Expansion of the virus in allogenic system

Treatment with both MTIs and NAM exhibited a common feature in terms of viral purging: blunted HIV recovery with fluctuating viral loads that either increased over time or declined, despite cultures being continually fed with new CD8-depleted and PHA-activated/LRAs treated PBMCs (Fig. 1A and B). Seven samples treated with MTIs and five treated with NAM showed an increase in viral load over a course of 29 and 18 days, respectively. On the other hand, seven samples of MTIs group and four from NAM showed decrease in viral loads.

Sample (S31) treated with MTIs showed abnormal behavior in the culture. It turned positive at day 10 (third collection) but returned to negative in the next two subsequent collections although the culture was fed with new round of MTIs treated CD8-depleted autologous PBMCs and the medium was being replenished every third or fourth day. It turned positive again at day 21 (sixth collection) when it was fed for the third time with a new round of cells. At the seventh collection, the viral load was undetectable again showing extinction of the virus according to viral load assay. This sample turned positive again at ninth collection after a fourth round of feeding with autologous cells, presenting a viral load of 10,014 copies/ml (Fig. 1A).

We hypothesized that this fluctuation of viral loads could be related to some sort of host restriction interfering with the viral replication. To resolve this, we selected nine samples and expanded these viruses in allogenic system and observed the

same behavior of the viruses, showing declining of viral load and ultimate extinction (Supplementary Table S1).

Cultures were repeated with a lower multiplicity of infection (MOI) in order to avoid the impact of defective interfering particles. Again, after an initial HIV recovery, cultures evolved to a rapid HIV extinction (data not shown). This excluded the possibility of host specific restrictions but raised suspicion that purged viruses among these ART suppressed individuals might be defective.

p24 Quantification

In order to check the specificity of HIV-viral loads in quantifying alleged defective strains, 18 samples were selected with low, intermediate, and high viral load to quantify p24 antigen. p24 could only be quantified in those samples that had intermediate and/or high viral loads with proportional results between the two systems (Supplementary Table S2).

Viral extinction correlates with defective virions observed by EM

After observing anomalous behavior of the virus in autologous as well as allogenic system, we visually inspected the virus by EM (Fig. 2E and F). We randomly selected five supernatant samples. EM revealed abnormal features in all inspected viral particles, such as smaller size (30–90 nm in diameter), distinct electron dense central cores could not be seen and fully double ring particles were very infrequent. The projections on the viral envelope could not be clearly discerned, in some cases particles were doughnut shaped double ringed structure with an electron lucent center.²⁵

Characterization of HIV-1 RNAs reactivated *ex vivo* by LRAs

The abnormal viral propagation in *ex vivo* cultures and compromised morphology seen by EM was suggestive of massive presence of defective particles post LRA stimulation. To confirm this, metagenomics UDS was performed. According to this approach, an equal number of reads throughout the HIV-1 genome was expected since random primers were used. However, we were not able to recover full-length genome data from the cell culture supernatants by UDS methodology and analysis. The number of reads was completely uneven which suggests that HIV-1 genome from the supernatant contains major deletions causing the particles to be defective, as previously described.²⁶ Although the coverage was not optimal but in two samples, S7 and NA5, treated *in vitro* with MTIs and NAM, respectively, we were able to recover partial to complete genomes (Fig. 2A and B). NA5 showed missing patches of *gag* and *nef* in its genome. While the sequencing data from NA8 showed three stretches of envelope gene encompassing position 6920–8271bp (Fig. 2D) and S2 showed partial complete genome encompassing 2389–8078 bp (Fig. 2C). This lack of complete genome in these two samples is in agreement with anomalous viral particles seen by EM (Fig. 2E and F) and extinction of the viruses observed in allogenic system (Supplementary Table S1).

Altogether, the whole sequencing data suggests that viral particles purged after NAM and MTIs stimulation from patients had packaged incomplete HIV-genome in them. We understand that this virus is not able to make a complete next round of infection (Additional file 1: Table S1).

Discussion

This is the first demonstration in HIV-infected *ex vivo* primary cell cultures that NAM, a Vitamin B, causes purging of dormant provirus with short-term treatment and notably high virus production. Considering reactivation in *ex vivo* assays with different LRAs like Chaetocin, BIX01294, Romidopsin, Panobinostat, and Bryostatins, we observed significantly higher virus production in the cultures treated with NAM. However, direct comparison with Panobinostat, Romidopsin, and Bryostatins has not been performed in this study.

We used two already reported MTIs, Chaetocin and BIX01294,¹⁹ and NAM to compare combination of two LRAs (MTIs) versus one NAM. A significant difference was observed in culture viral loads post-treatment (Fig. 1D) and purging of virus in terms of the time required for virus to emerge in the culture (Fig. 1C), although the wide standard deviation in viral loads after use of LRAs reinforces the unpredictable nature of the magnitude of viral purging. Cultures that stayed negative post MTIs treatment were kept for a mean time of 20 days (14–30 days) and in NAM for a mean time of 10 days only (7–17 days). It is conceivable that if cultures treated with NAM were also kept and fed for a longer period as were kept for MTIs, more efficient purging of the viruses from NAM treated samples would occur. Unfortunately, these cultures could not be maintained for longer periods due to unavailability of autologous cells for continuous feeding.

To find a correlation between viral purging and the proviral compartment, we were able to quantify proviral DNA in 14 available samples exposed *ex vivo* to MTIs. Sample (S13) remained negative for proviral load as well as in *ex vivo* culture. Therefore, we hypothesized that the HIV proviral compartment of this individual might be very low, preventing an efficient *in vitro* purging using MTIs. However, in the remaining 13 samples, no correlation was found between proviral loads and efficacy of LRA, time to virus purging and viral load at purging.

In vitro stimulation of T-lymphocytes by cytokines, lymphokines and mitogens contributes to their activation and proliferation by activating transcription factors such as NFκB. The HIV-1 promoter contains two tandem NFκB binding sites (κ response elements). Besides HIV-1, the IL-2 promoter also contains binding sites for NFκB.²⁷ Thus, NFκB binding to its response elements can lead to the activation of respective promoters. Also, the p65 subunit of NFκB helps in activation of the HIV promoter by recruiting PTEFb (CDK9, Cyclin T1)²⁸ which phosphorylates C-terminal domain (CTD) of RNA polymerase II.¹⁶ Thus, once a T cell is stimulated, it allows resting CD4+ T cells to undergo a burst of cellular proliferation and differentiation, giving rise to effector cells and thus breaking latency.

Although direct molecular mechanism using specific inhibitor/antibody of SIRT in combination with NAM has not




Fig. 2 – Characterization of the purged viruses using Next Generation sequencing with Metagenomics Methodology for *de novo* HIV characterization on supernatant samples containing purged HIV-1 particles of 4 selected samples following *in vitro* treatment with the MTIs association (patients S7 and S2, panels A and C) and NAM (patients NA5 and NA8, panels B and D) showing uneven coverage of HIV genome. Panels E and F shows the electronic microscopy result performed in the supernatant of samples S2 and NA8 respectively showing anomalous HIV particles.

been performed here, literature suggests that NAM can act as an LRA in several ways. (i) NAM is a deacetylase inhibitor because it blocks SIRT1, a class III HDAC, and thus inhibits deacetylation of histones and the consequent formation of facultative heterochromatin [reviewed in Ref. 11]. (ii) Alternatively, NAM may be directly salvaged back to NAD during biosynthesis and can act as an indirect activator of SIRT1.²⁹ Its activation can break latency in two different ways. First, it

can deacetylate various substrates, like the viral TAT protein³⁰ and the p53 subunit of NFκB. TAT binds to SIRT1 and blocks deacetylation of the p53 subunit.¹⁷ This makes p53 subunit remain free and it can recruit PTEFb which phosphorylates CTD of RNAPII causing promotor activation and latency break. The deacetylated form of TAT, which is the only form able to engage in the formation of the TAT/TAR/P-TEFb complex, is thus available to the cell when SIRT1 is catalytically active in

the presence of NAD. Secondly, SUV39, a methyltransferase, is another substrate of SIRT1³¹ that favors latency by adding a methyl group to the histone proteins. Therefore, active SIRT1 can also deacetylate SUV39 thus avoiding chromatin condensation resulting in latency break.

Over 90% of proviruses in the peripheral blood are considered to be defective due to lethal genetic mutations that include G-to-A hypermutations and small insertions/deletions that interrupt ORFs, or even large deletions.³² It has been recently demonstrated that during long-term ART, the proportion of replication competent proviral compartment decreases over time as compared to defective HIV³³ which suggests that replication competent provirus are coming out of latency over time³⁴ leading to cell death by cytopathic effects and/or immune clearance. The participants of this study are under long-term ART with a mean duration of nine years (range: 3–20) conceivably harboring massive presence of defective provirus, confirmed by propagation of virus in autologous (Fig. 1A and B) as well as in allogenic system (Supplementary Table S1) and viral particles observed by electron microscopy which revealed anomalous HIV particles (Fig. 2E and F). Small sized particles seen by EM might have been purged from the cells harboring defective small proviral genome. We recognize that the absence of a positive control sample, such as a laboratory-adapted virus strain using a standard packaging cell line to compare with the patient-derived HIV, may preclude the conclusions whether some external factors could be altering the virus particles morphology analyzed by electronic microscopy or the “*de novo*” genomic sequencing results. However, several reports have demonstrated that the defective HIV obtained from individuals under long-term ART may present as small as 2 kb proviral DNA.^{26,35} This is consistent with the finding of partial to complete genomes in our samples by UDS. From a virologic point of view, it is non-infectious material of no consequence. However, from an immunologic standpoint, it is the by-product of a viral mechanism to stay one-step ahead of the cellular and humoral responses.

The potential of these MTIs and NAM are evident by virus production shortly after stimulation of the samples with undetectable viral loads. However, we recognize some weaknesses of this study. We have not been able to use purified cell populations to determine the source of viral emergence. In addition, the limited number of cells from the same HIV donor precluded comparison by pairing the samples for both purging strategies to better determine the efficacy of each LRA separately or in synergy. Among the negative samples, only NA9 and S6 could be tested for both LRAs, treated separately and in combination to see any synergistic effect, if existed. However, no viral purging was observed. Individual NA9, a 39-year old male, was treated early in his HIV infection, with a recent seroconversion (HIV negative EIA six months before diagnosis and treatment initiation) and a CD4+ T lymphocytes count of 851 cells/mm³. This individual presented only one pre-treatment positive viral load of 37,660 copies/mL and was exposed to Tenofovir, 3TC and Efavirenz for three years. By the time the samples were drawn for HIV culture, a rapid HIV EIA test was repeatedly negative in the plasma sample (TR DPP[®] HIV1/2, Bio-Manguinhos, Rio de Janeiro, Brazil), although a regular 4th generation EIA test and Western blot were positive, which suggest a low level of HIV antibodies. Furthermore, nested PCR for

the V3 region of the envelope gp120, envelope gp41, protease and reverse transcriptase of *pol* gene, and *gag* P17 were all negative for this patient. This individual presented a wild type CCR5 allele (data not shown). S6 was nested PCR positive for the V3 region of the gp120, with a genotype compatible with a non-R5 strain, and was heterozygous for CCR5 (CCR5 Δ 32/wild type). Considering that viral purging is interplay between (i) host transcription factors, (ii) LRAs, and (iii) viral protein (TAT), it is not clear whether culture negativity was related to a specific host restriction, overwhelming presence of defective viruses, viral integration site, epigenetic state, or lack of proper interaction between the drugs and latent cells. In addition, it is important to realize that the fate of cells expressing pharmacologically reactivated proviruses is not fully understood i.e., reactivation of latent HIV with NAM or other LRAs would lead to virus-induced cell death by direct or bystander mechanisms.

Our *ex vivo* results essentially brought NAM use as anti-latency drug. However, further studies are needed to determine its dose dependent effects on viral load, immune function and clinical outcomes in virally suppressed individuals. It should be noted that SIRT1 has a complex biology given the multiplicity of activities attributed to its sub-cellular localization and multitude of substrates. It has gained considerable interest by the pharmaceutical industry as a prospective drug target for the treatment of metabolic disease, cancer, inflammation, and/or neurodegeneration.³⁶ Owing to SIRT1 complexity, appropriate animal models will also be important to understand NAM/SIRT1 biology in context of HIV infection to break latency. More potent and selective inhibitors of SIRT1 will need to be tested *in vivo* to unequivocally answer this question. Of note, NAM has been used in clinical medicine for a number of distinct purposes with a very safe profile.³⁷

In conclusion, our observations provide the first evidence that NAM has a latency reversal activity with a potency and efficacy conceivably superior to the combination of two MTIs. NAM acts as a double edge sword as it can break HIV-1 latency by directly inhibiting SIRT1 or indirectly via NAD biosynthesis as an intermediate compound and activating SIRT-1. Thus, early purging induced by NAM with significantly high viral load could be due to more than one mechanism being stimulated simultaneously. Decrease in NAD level has been reported in HIV infection¹⁸ and since NAM has a central role in cellular metabolism, it is plausible that NAM supplementation can restore NAD levels and might also help in regulating the redox environment among HIV infected individuals. In addition, our data suggests that cells harboring defective proviral pool can produce defective viral particles, once they are stimulated and may be responsible for seropositivity, persistent immune activation and residual viremia among individuals with suppressed viremia. New latency reversal strategies must be designed aimed at eliminating those cells harboring this defective proviral pool to obtain HIV SVR.

Authors' contributions

SS, TMO, SVK, LMJ, MCS and RSD designed the experiments. SS, MSA, LBG, BTL, GN and JG performed the experiments. SS, TMO, SVK, MCS, LMJ and RSD analyzed the data. SS and GN

performed electron microscopy. JH did the statistical analysis. JPLZ performed NGS analysis. SS, MSA, LBG, JPLZ, JH, BTL, GN, LMJ and RSD prepared the manuscript. All authors reviewed the manuscript.

Competing financial interests

The authors have declared that no competing interests exist.

Ethics approval and consent to participate

This study and the ICF have been approved by the Ethical Review Board in Brazil under the number 226.613, CAAE 10757312.0.000.5505. Informed written consent was obtained from all patients.

Consent for publication

All authors have read and approved the manuscript for publication.

Funding

This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 2013/11323-5) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 454700/2014-8). SS, MAS, LBG and JPZ received PhD fellowship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazilian Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and material

All the sequence data generated in this study have been submitted to NCBI Genbank Database. Accession numbers (pending).

Acknowledgements

We are grateful to all HIV-infected patients who participated in the study by donating their blood.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.bjid.2020.01.005>.

REFERENCES

- Pinzone MR, Cacopardo B, Condorelli F, Di Rosa M, Nunnari G. Sirtuin-1 and HIV-1: an overview. *Curr Drug Targets*. 2013;14:648–52.
- Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. *Nat Med*. 2009;15:893–900.
- Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. *Lancet*. 2013;381:2109–17.
- Sogaard OS, Graversen ME, Leth S, et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. *PLoS Pathog*. 2015;11, e1005142.
- Bernhard W, Barreto K, Saunders A, Dahabieh MS, Johnson P, Sadowski I. The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response. *FEBS Lett*. 2011;585:3549–54.
- Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. *Antimicrob Agents Chemother*. 2015;59:5984–91.
- Imai K, Togami H, Okamoto T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. *J Biol Chem*. 2010;285:16538–45.
- Vergara TRC, Samer S, Santos-Oliveira JR, et al. Thalidomide is Associated with Increased T Cell Activation and Inflammation in Antiretroviral-naive HIV-infected Individuals in a Randomised Clinical Trial of Efficacy and Safety. *EBioMedicine*. 2017;(August), <http://dx.doi.org/10.1016/j.ebiom.2017.08.007>. PMID:28822719, pii: S2352-3964(17)30324-9.
- Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. *Oncogene*. 2007;26:5310–8.
- Gross JW, Rajavel M, Grubmeyer C. Kinetic mechanism of nicotinic acid phosphoribosyltransferase: implications for energy coupling. *Biochemistry*. 1998;37:4189–99.
- Khan JA, Forouhar F, Tao X, Tong L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. *Expert Opin Ther Targets*. 2007;11:695–705.
- Guan X, Lin P, Knoll E, Chakrabarti R. Mechanism of inhibition of the human sirtuin enzyme SIRT3 by nicotinamide: computational and experimental studies. *PLoS One*. 2014;9(9):e107729, <http://dx.doi.org/10.1371/journal.pone.0107729>, eCollection 2014.
- Stevens M, De Clercq E, Balzarini J. The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. *Med Res Rev*. 2006;26:595–625.
- Barboric M, Peterlin BM. A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation. *PLoS Biol*. 2005;3:e76.
- Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. *EMBO J*. 2004;23:2369–80.
- Blazek D, Peterlin BM: Tat-SIRT1 tango. *Mol Cell*. 2008;29:539–40.
- Kwon HS, Brent MM, Getachew R, et al. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. *Cell Host Microbe*. 2008;3:158–67.
- Murray MF, Nghiem M, Srinivasan A. HIV infection decreases intracellular nicotinamide adenine dinucleotide [NAD]. *Biochem Biophys Res Commun*. 1995;212:126–31.
- Bouchat S, Gatot JS, Kabeya K, et al. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. *AIDS*. 2012;26:1473–82.
- Komninakis S, Santos D, Santos C, Oliveros M, Sanabani S, Diaz RS. HIV-1 Proviral DNA load (qPCR) in patients subjected

- to Structured Treatment Interruption (STI) after antiretroviral therapy failure. *J Clin Microbiol.* 2012;50(June (6)):2132-3. PMID:22422851.
21. Lavigne S, Santos C, Arif MS, et al. Short communication: HIV type 1 tropism determination in a novel dried blood spot membrane and the use of a mixture of outer nested polymerase chain reaction primers. *AIDS Res Hum Retroviruses.* 2014;30:147-50.
 22. Arif MS, Hunter J, Leda AR, et al. Pace of Coreceptor Tropism Switch in HIV-1-Infected Individuals after Recent Infection. *J Virol.* 2017;91(19), <http://dx.doi.org/10.1128/JVI.00793-17>, pii: e00793-17. Print 2017 Oct 1.
 23. Li L, Deng X, Mee ET, Collet-Teixeira S, Anderson R, Schepelmann S, Minor PD, Delwart E. Comparing viral metagenomics methods using a highly multiplexed human viral pathogens reagent. *J Virol Methods.* 2014;213:139-46.
 24. Brenner S, Horne RW. A negative staining method for high resolution electron microscopy of viruses. *Biochim Biophys Acta.* 1959;34:103-10.
 25. Samer S, Namiyama G, Oshiro T, et al. Evidence of Noncompetent HIV after Ex Vivo Purging Among ART-Suppressed Individuals. *AIDS Res Hum Retroviruses.* 2017;33(October (10)):993-4, <http://dx.doi.org/10.1089/aid.2017.0036>.
 26. Imamichi H, Dewar RL, Adelsberger JW, et al. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy. *Proc Natl Acad Sci U S A.* 2016;113:8783-8.
 27. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. *Clin Microbiol Rev.* 2001;14:753-77, table of contents.
 28. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. *Mol Cell.* 2001;8:327-37.
 29. Yang H, Lavu S, Sinclair DA. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? *Exp Gerontol.* 2006;41:718-26.
 30. Pagans S, Pedal A, North BJ, et al. SIRT1 regulates HIV transcription via Tat deacetylation. *PLoS Biol.* 2005;3:e41.
 31. Vaquero A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L, Reinberg D. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. *Nature.* 2007;450:440-4.
 32. Imamichi H, Natarajan V, Adelsberger JW, et al. Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus. *AIDS.* 2014;28:1091-9.
 33. Sanchez G, Xu X, Chermann JC, Hirsch I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. *J Virol.* 1997;71:2233-40.
 34. Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. *Ann Intern Med.* 2014;161:319-27.
 35. Bruner KM, Murray AJ, Pollack RA, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. *Nat Med.* 2016;22:1043-9.
 36. Stunkel W, Campbell RM. Sirtuin 1 (SIRT1): the misunderstood HDAC. *J Biomol Screen.* 2011;16:1153-69.
 37. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. *Diabetologia.* 2000;43:1337-45.